Furthermore, in 2022, a large scale multicenter international RCT (the EMPA-KIDNEY trial) revealed the renal protective effects of SGLT2 inhibitors even in non-DKD CKD patients [112], with their efficacy being even more prominent in those in whom the albumin-to-creatinine ratio was more than 300 mg/g [112]. The gene discussed is ALB; the disease is diabetic kidney disease.